Lupus (SLE): vizsgálatok itt: Belgium
15 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Ghent, Leuven
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- Leuven
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Gent, Sint-Lambrechts-Woluwe
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Leuven, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - 1. fázisTaking peopleA Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
- Where
- Diepenbeek, Gent
- Életkor
- 18 év to 75 év
- People
- 21 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07363590 · EU 2025-523412-36-00 - 1. fázisTaking peopleStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- Antwerp, Edegem, Leuven, Liège
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 2. fázisTaking peopleA Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
- Where
- Brussels, Gent, Leuven, Liège
- Életkor
- 5 év to 17 év
- People
- 24 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07630714 · EU 2025-524578-41-00 - 3. fázisNot yet taking people in BelgiumRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Gent
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 · EU 2026-526419-13-00 - 3. fázisCsak meghívásosA Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus
- Where
- Anderlecht, Leuven, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 16 év and over
- People
- 760 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT04976322 · EU 2023-506368-14-00 - 1. fázisNot yet taking people in BelgiumA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Leuven
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 1. fázisNot yet taking people in BelgiumA study to learn how dapirolizumab pegol transfers to babies from pregnant mothers with active systemic lupus erythematosus
- Where
- Leuven
- Életkor
- Up to 64 év
- People
- 10 worldwide
- Run by
- UCB Biopharma
See details and how to join2025-524595-37-00 · EU 2025-524595-37-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Liège
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 2. fázisTaking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Brussels, Ghent, Leuven, Liège
- Életkor
- 18 év to 75 év
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - No phaseTaking peopleMedical Follow-up of New Cases of Polyarthritis in Children and Young Adults
- Where
- Brussels
- Életkor
- 2 év to 50 év
- People
- 1000
- Run by
- Université Catholique de Louvain
See details and how to joinNCT07000916 - No phaseTaking peopleDisease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
- Where
- Brussels
- Életkor
- 18 év to 70 év
- People
- 250
- Run by
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
See details and how to joinNCT05443516